Examining the Safety Profiles of SG and Pembrolizumab in ASCENT-04

In the ASCENT-04 study, clinicians had the opportunity to evaluate the safety profile of the sacituzumab govitecan (SG) and pembrolizumab combination in comparison with standard chemotherapy plus pembrolizumab. These findings highlight that while high-grade toxicities are frequent in both arms, the nature of adverse events differs between the regimens. The SG/pembrolizumab combination was associated with manageable non-hematologic events, whereas chemotherapy-related toxicity was largely hematologic, informing clinicians’ considerations for monitoring and supportive care in routine practice.